Literature DB >> 28814704

[Clinical Evaluation of Urosepsis in Tane General Hospital ; Clinical Utility of Measurement of Procalcitonin].

Yukinari Hosokawa1, Takuto Shimizu1, Takuya Owari2, Kenji Otsuka1, Yoshiki Hayashi1, Kiyohide Fujimoto2.   

Abstract

We clinicaliye valuated 355 patients with urinarytract infections (UTI), suspected of having urosepsis at Tane General Hospital, and determined the usefulness of the biomarker procalcitonin (PCT) as an aid in predicting urosepsis. Clinical and microbiological data were collected. The logistic regression analysis was used to determine the risk factors of urosepsis. Of 355 patients, 169 patients (47.6%) were diagnosed with urosepsis. C-reactive protein (CRP) (OR 2. 633, p<0. 001), PCT (OR 2. 153, p=0. 003) and clinical diagnosis (calculous pyelonephritis OR 1. 886, p=0. 019, acute prostatitis OR 3. 614, p<0. 001) were established as the independent risk factors of urosepsis. Of 169 patients with urosepsis, 43 patients (25.4%) were diagnosed with severe urosepsis. In the severe urosepsis group, 2 patients with a PCT value <2.0 ng/ml were included. The mortalityrate in patients with severe urosepsis was 4.65% (2/43) in this study. We concluded that the PCT level could be a reliable marker suggestive of urosepsis. However, patients very early in the onset of infection mayhave a normal PCT value. It is essential to use all available clinical information when interpreting the results of a PCT measurement.

Entities:  

Keywords:  Procalcitonin; Urosepsis

Mesh:

Year:  2017        PMID: 28814704     DOI: 10.14989/ActaUrolJap_63_7_259

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  2 in total

1.  Research on the Correlation of Serum PCT and Plasma GSN Levels with the Prognosis of Urosepsis Patients.

Authors:  Na Cui; Zhanbiao Yu; Zhi Chen; Ning Chen
Journal:  Pak J Med Sci       Date:  2020 Jul-Aug       Impact factor: 1.088

2.  Diagnostic Value of Inflammatory Markers and Cytokines in Neonatal Sepsis.

Authors:  Lijie Wu; Jinku Li; Lili Ping; Xiaoli Zhang; Lina Zhai; Yanmin Li; Ruimin Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-11       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.